Table 1 Clinical characteristics of the 75 reported cases of fibronectin glomerulopathy
Age | Sex | UP | Cre | Comorbidity | Family history | FN1 mutation | ||
|---|---|---|---|---|---|---|---|---|
1 | Strøm et al. | 59 | F | 3.9 | 1.0 | NA | + | NA |
2 | 18 | M | 4.5 | 1.2 | NA | + | NA | |
3 | 24 | M | 14.0 | 1.0 | NA | + | NA | |
4 | 21 | M | 2–4 | 1.0 | NA | + | NA | |
5 | 19 | M | NA | NA | NA | + | NA | |
6 | 22 | F | NA | NA | NA | + | NA | |
7 | 25 | F | 5.0 | NA | NA | + | NA | |
8 | 14 | F | NS | 0.6 | NA | + | NA | |
9 | 64 | M | 2.0 | 1.1 | NA | + | NA | |
10 | 16 | M | 5.0 | NA | NA | + | NA | |
11 | 23 | M | 0.6 | 0.8 | NA | + | NA | |
12 | 25 | F | 0.3 | 0.8 | NA | + | NA | |
13 | 30 | M | 2.1 | 1.3 | NA | + | NA | |
14 | 24 | M | 1.3 | 1.4 | NA | + | NA | |
15 | 26 | F | + | NA | cerebrovascular hemorrhage | + | NA | |
16 | 29 | M | 3+ | 1.8 | cerebrovascular hemorrhage | + | NA | |
17 | 15 | M | 4+ | NA | cerebrovascular hemorrhage myocardial infarction | + | NA | |
18 | 14 | M | 3+ | 0.8 | NA | + | NA | |
19 | 44 | M | 4.7 | 1.6 | NA | + | NA | |
20 | 37 | F | 0.7 | 0.9 | NA | + | NA | |
21 | 33 | M | 1.0 | 1.0 | NA | + | NA | |
22 | 31 | M | 2.1 | 1.0 | NA | + | NA | |
23 | 53 | M | NS | NA | renal cell carcinoma | + | NA | |
24 | Gemperle et al. | 35 | F | 5.6 | NA | NA | + | NA |
25 | 31 | M | 1.8 | NA | myocardial infarction | + | NA | |
26 | 38 | M | + | NA | NA | + | NA | |
27 | 46 | F | 0.1 | NA | NA | + | NA | |
28 | 42 | M | + | NA | renal cell carcinoma | + | NA | |
29 | 30 | M | 0.5 | NA | myocardial infarction | + | NA | |
30 | 33 | F | 0.7 | NA | NA | + | NA | |
31 | 32 | M | 1.0 | NA | myocardial infarction | + | NA | |
32 | 20 | M | + | NA | NA | + | NA | |
33 | Sato et al. | 23 | M | 2.0 | 0.9 | NA | + | NA |
34 | Uesugi et al. | 4 | M | 8.0 | 0.2 | NA | + | NA |
35 | 19 | F | 7.0 | 0.6 | NA | NA | NA | |
36 | 27 | M | 1.0 | 0.8 | NA | + | NA | |
37 | 58 | M | 12.0 | 1.6 | NA | + | NA | |
38 | 75 | M | 2.1 | NA | NA | + | NA | |
39 | Niimi et al. | 3 | M | 8.0 | 0.2 | NA | + | NA |
40 | Castelletti et al. | 59 | F | NS | Nomal | NA | + | + |
41 | 44 | M | 0.3 | 1.4 | NA | + | + | |
42 | 40 | M | NA | 2.2 | NA | + | + | |
43 | 35 | M | NS | 1.5 | NA | + | + | |
44 | 18 | M | 4.2 | 1.4 | NA | + | + | |
45 | 27 | M | 0.7 | 0.8 | NA | + | + | |
46 | 16 | M | NA | Nomal | NA | + | + | |
47 | 12 | M | 7.5 | 0.7 | NA | + | + | |
48 | Yong et al. | 41 | M | NS | 1.7 | NA | + | NA |
49 | Nadamuni et al. | 50 | F | 4.8 | 0.8 | anxiety, depression | + | + |
50 | Otsuka et al. | 52 | F | 0.4 | 1.5 | atrial septal defect tricuspid regurgitation | − | NA |
51 | Yoshino et al. | 67 | M | 3.6 | 1.7 | thymic carcinoid gastric cancer | − | NA |
52 | Baydar et al. | 24 | M | 1.0 | 0.8 | asthma | + | + |
53 | Ishimoto et al. | 78 | F | 10.2 | 1.1 | NA | − | − |
54 | Chen et al. | 34 | F | 3.6 | 0.7 | NA | − | NA |
55 | 24 | M | 3.9 | 2.0 | NA | − | NA | |
56 | 46 | M | 3.7 | 0.8 | NA | + | NA | |
57 | 32 | M | 1.2 | 0.9 | NA | − | NA | |
58 | 27 | F | 3.8 | 0.5 | NA | − | NA | |
59 | 26 | M | 7.4 | 1.5 | NA | − | NA | |
60 | 19 | M | 9.1 | 1.4 | NA | − | NA | |
61 | 32 | F | 9.1 | 3.4 | NA | − | NA | |
62 | 29 | M | 7.0 | 1.5 | NA | − | NA | |
63 | 19 | F | 2.8 | 0.6 | NA | − | NA | |
64 | Ohtsubo et al. | 20 | M | 0.86 | 92.1a | NA | + | + |
65 | 13 | F | 1.6 | 115a | NA | − | + | |
66 | 35 | F | ESRD | ESRD | NA | + | + | |
67 | 54 | F | ESRD | ESRD | NA | + | + | |
68 | 35 | F | 5.85 | 76.3a | NA | − | + | |
69 | 15 | F | 0.51 | 86.5a | NA | + | + | |
70 | 53 | F | 11.8 | 48a | NA | − | + | |
71 | 16 | M | 0.44 | 124.1a | NA | − | + | |
72 | 74 | M | 3.56 | 63a | NA | − | + | |
73 | 38 | F | 4.9 | 55.3a | NA | + | + | |
74 | 14 | F | 10.1 | 123.4a | NA | − | + | |
75 | 64 | M | 4.6 | 46.3a | NA | − | + | |
76 | This case | 21 | F | 3.4 | 0.7 | persistent cloaca congenital esophageal atresia | − | − |